HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Improved antitumor activity of basic amino acid and dipeptide derivatives of daunorubicin on EL4 leukemia cells in mice.

Abstract
Over thirty amino acid and peptide derivatives of the antitumor drug daunorubicin (DM) were tested for their potency to inhibit EL4 leukemia cell growth in mice. The therapeutic effect of the basic amino acids lysine, arginine, ornithine, and 2,4-diaminobutyric acid coupled to the amino group of the DM moiety proved superior to that of the parent drug. The derivatized amino acids and their di- or tripeptides are significantly less toxic than DM, which enabled their administration at much higher doses. Seventy percent to 80% of tumor-bearing C57BL/6 mice were cured by multidose treatment with diaminobutyryl-DM, which was found to be the most efficient derivative.
AuthorsB A Sela, Y Levin
JournalCancer treatment reports (Cancer Treat Rep) 1981 Mar-Apr Vol. 65 Issue 3-4 Pg. 277-81 ISSN: 0361-5960 [Print] United States
PMID7237450 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Amino Acids
  • Antineoplastic Agents
  • Peptides
  • Daunorubicin
Topics
  • Amino Acids
  • Animals
  • Antineoplastic Agents (toxicity)
  • Daunorubicin (analogs & derivatives, metabolism, toxicity)
  • Leukemia, Experimental (drug therapy, metabolism, pathology)
  • Mice
  • Mice, Inbred C57BL
  • Neoplasm Transplantation
  • Peptides

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: